Japanese drugmaker Eisai (TYO: 4523) has backed out of its 50:50 profit sharing deal with US biotech company Biogen (Nasdaq: BIIB) on the Alzheimer’s drug Aduhelm (aducanumab).
Effective as of January 1, 2023, Eisai will receive tiered royalties based on net sales of Aduhelm rather than sharing global profits and losses. The royalty rate starts at 2% and reaches 8% when, or if, annual sales exceed $1 billion.
"The goal of maximizing the value of both Aduhelm and lecanemab"As from now, Biogen’s existing final decision-making rights on Aduhelm have converted to sole decision making and commercialization rights worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze